Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project

Standard

Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project. / Rehm, Martin; Rothenbacher, Dietrich; Iacoviello, Licia; Costanzo, Simona; Tunstall-Pedoe, Hugh; Fitton, Catherine A; Söderberg, Stefan; Hultdin, Johan; Salomaa, Veikko; Jousilahti, Pekka; Palosaari, Tarja; Kuulasmaa, Kari; Waldeyer, Christoph; Schnabel, Renate B; Zeller, Tanja; Blankenberg, Stefan; Koenig, Wolfgang; BiomarCaRE Consortium.

In: ESC HEART FAIL, Vol. 9, No. 1, 02.2022, p. 57-65.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Rehm, M, Rothenbacher, D, Iacoviello, L, Costanzo, S, Tunstall-Pedoe, H, Fitton, CA, Söderberg, S, Hultdin, J, Salomaa, V, Jousilahti, P, Palosaari, T, Kuulasmaa, K, Waldeyer, C, Schnabel, RB, Zeller, T, Blankenberg, S, Koenig, W & BiomarCaRE Consortium 2022, 'Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project', ESC HEART FAIL, vol. 9, no. 1, pp. 57-65. https://doi.org/10.1002/ehf2.13699

APA

Rehm, M., Rothenbacher, D., Iacoviello, L., Costanzo, S., Tunstall-Pedoe, H., Fitton, C. A., Söderberg, S., Hultdin, J., Salomaa, V., Jousilahti, P., Palosaari, T., Kuulasmaa, K., Waldeyer, C., Schnabel, R. B., Zeller, T., Blankenberg, S., Koenig, W., & BiomarCaRE Consortium (2022). Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project. ESC HEART FAIL, 9(1), 57-65. https://doi.org/10.1002/ehf2.13699

Vancouver

Bibtex

@article{2dd73819d7f247e7a0a854a41264b99b,
title = "Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project",
abstract = "AIMS: Chronic kidney disease (CKD) has a complicated relationship with the heart, leading to many adverse outcomes. The aim of this study was to evaluate the relationship between CKD and the incidence of atrial fibrillation (AF) and heart failure (HF) along with mortality as a competing risk in general population cohorts. We also included an assessment of baseline biomarkers of inflammation, myocardial injury, and left ventricular dysfunction with risk of AF and HF, respectively, to shed light on the potential underlying pathophysiology.METHODS AND RESULTS: This study was conducted within the BiomarCaRE project using harmonized data from 12 European population-based cohorts (n = 48 518 participants). Renal function was assessed by glomerular filtration rate estimated using the combined Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation with standardized serum creatinine (Cr) and non-standardized serum cystatin C (CysC). Incidence of AF and HF respectively, during a median follow-up of 8 years was recorded. Cox proportional hazards models were used to determine hazard ratios (HRs) for the incidence of AF and HF in CKD and the competing risk of mortality after adjustment for covariates. The mean age at baseline was 51.4 (standard deviation 12.1) years, 49% were men. Overall, 4.3% of subjects had CKD at baseline. The rate for AF was 3.8 per 1000 person-years during follow-up. The HR for AF in patients with CKD compared with patients without CKD was 1.28 (95% confidence interval 1.07-1.54) after adjustment for covariates. The rate for incident HF was 4.1 per 1000 person-years and the HR of CKD for HF was 1.71 (95% confidence interval 1.45-2.01. In subjects with CKD, N-terminal-pro-brain natriuretic peptide (NT-proBNP) showed an association with AF, whereas NT-proBNP and C-reactive protein were associated with HF.CONCLUSIONS: Chronic kidney disease is an independent risk factor for subsequent AF and is even more closely associated with HF. In these relatively young participants with CKD, NT-proBNP was strongly associated with subsequent risk of AF. For HF, in addition, elevated levels of hs-C-reactive protein at baseline were related to incident events.",
author = "Martin Rehm and Dietrich Rothenbacher and Licia Iacoviello and Simona Costanzo and Hugh Tunstall-Pedoe and Fitton, {Catherine A} and Stefan S{\"o}derberg and Johan Hultdin and Veikko Salomaa and Pekka Jousilahti and Tarja Palosaari and Kari Kuulasmaa and Christoph Waldeyer and Schnabel, {Renate B} and Tanja Zeller and Stefan Blankenberg and Wolfgang Koenig and {BiomarCaRE Consortium}",
note = "{\textcopyright} 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.",
year = "2022",
month = feb,
doi = "10.1002/ehf2.13699",
language = "English",
volume = "9",
pages = "57--65",
journal = "ESC HEART FAIL",
issn = "2055-5822",
publisher = "The Heart Failure Association of the European Society of Cardiology",
number = "1",

}

RIS

TY - JOUR

T1 - Chronic kidney disease and risk of atrial fibrillation and heart failure in general population-based cohorts: the BiomarCaRE project

AU - Rehm, Martin

AU - Rothenbacher, Dietrich

AU - Iacoviello, Licia

AU - Costanzo, Simona

AU - Tunstall-Pedoe, Hugh

AU - Fitton, Catherine A

AU - Söderberg, Stefan

AU - Hultdin, Johan

AU - Salomaa, Veikko

AU - Jousilahti, Pekka

AU - Palosaari, Tarja

AU - Kuulasmaa, Kari

AU - Waldeyer, Christoph

AU - Schnabel, Renate B

AU - Zeller, Tanja

AU - Blankenberg, Stefan

AU - Koenig, Wolfgang

AU - BiomarCaRE Consortium

N1 - © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

PY - 2022/2

Y1 - 2022/2

N2 - AIMS: Chronic kidney disease (CKD) has a complicated relationship with the heart, leading to many adverse outcomes. The aim of this study was to evaluate the relationship between CKD and the incidence of atrial fibrillation (AF) and heart failure (HF) along with mortality as a competing risk in general population cohorts. We also included an assessment of baseline biomarkers of inflammation, myocardial injury, and left ventricular dysfunction with risk of AF and HF, respectively, to shed light on the potential underlying pathophysiology.METHODS AND RESULTS: This study was conducted within the BiomarCaRE project using harmonized data from 12 European population-based cohorts (n = 48 518 participants). Renal function was assessed by glomerular filtration rate estimated using the combined Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation with standardized serum creatinine (Cr) and non-standardized serum cystatin C (CysC). Incidence of AF and HF respectively, during a median follow-up of 8 years was recorded. Cox proportional hazards models were used to determine hazard ratios (HRs) for the incidence of AF and HF in CKD and the competing risk of mortality after adjustment for covariates. The mean age at baseline was 51.4 (standard deviation 12.1) years, 49% were men. Overall, 4.3% of subjects had CKD at baseline. The rate for AF was 3.8 per 1000 person-years during follow-up. The HR for AF in patients with CKD compared with patients without CKD was 1.28 (95% confidence interval 1.07-1.54) after adjustment for covariates. The rate for incident HF was 4.1 per 1000 person-years and the HR of CKD for HF was 1.71 (95% confidence interval 1.45-2.01. In subjects with CKD, N-terminal-pro-brain natriuretic peptide (NT-proBNP) showed an association with AF, whereas NT-proBNP and C-reactive protein were associated with HF.CONCLUSIONS: Chronic kidney disease is an independent risk factor for subsequent AF and is even more closely associated with HF. In these relatively young participants with CKD, NT-proBNP was strongly associated with subsequent risk of AF. For HF, in addition, elevated levels of hs-C-reactive protein at baseline were related to incident events.

AB - AIMS: Chronic kidney disease (CKD) has a complicated relationship with the heart, leading to many adverse outcomes. The aim of this study was to evaluate the relationship between CKD and the incidence of atrial fibrillation (AF) and heart failure (HF) along with mortality as a competing risk in general population cohorts. We also included an assessment of baseline biomarkers of inflammation, myocardial injury, and left ventricular dysfunction with risk of AF and HF, respectively, to shed light on the potential underlying pathophysiology.METHODS AND RESULTS: This study was conducted within the BiomarCaRE project using harmonized data from 12 European population-based cohorts (n = 48 518 participants). Renal function was assessed by glomerular filtration rate estimated using the combined Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation with standardized serum creatinine (Cr) and non-standardized serum cystatin C (CysC). Incidence of AF and HF respectively, during a median follow-up of 8 years was recorded. Cox proportional hazards models were used to determine hazard ratios (HRs) for the incidence of AF and HF in CKD and the competing risk of mortality after adjustment for covariates. The mean age at baseline was 51.4 (standard deviation 12.1) years, 49% were men. Overall, 4.3% of subjects had CKD at baseline. The rate for AF was 3.8 per 1000 person-years during follow-up. The HR for AF in patients with CKD compared with patients without CKD was 1.28 (95% confidence interval 1.07-1.54) after adjustment for covariates. The rate for incident HF was 4.1 per 1000 person-years and the HR of CKD for HF was 1.71 (95% confidence interval 1.45-2.01. In subjects with CKD, N-terminal-pro-brain natriuretic peptide (NT-proBNP) showed an association with AF, whereas NT-proBNP and C-reactive protein were associated with HF.CONCLUSIONS: Chronic kidney disease is an independent risk factor for subsequent AF and is even more closely associated with HF. In these relatively young participants with CKD, NT-proBNP was strongly associated with subsequent risk of AF. For HF, in addition, elevated levels of hs-C-reactive protein at baseline were related to incident events.

U2 - 10.1002/ehf2.13699

DO - 10.1002/ehf2.13699

M3 - SCORING: Journal article

C2 - 34825788

VL - 9

SP - 57

EP - 65

JO - ESC HEART FAIL

JF - ESC HEART FAIL

SN - 2055-5822

IS - 1

ER -